Loading…
ANIX
Anixa Biosciences Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 03528H109
$3.48-3.33%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $118.4M
- P/E
- —
- Forward P/E
- —
- P/B
- 8.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.29
- ROE
- -71.97%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.52
- 52-week high
- $5.46
- 52-week low
- $2.32
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -41.7% over 5Y.
today you would have $582.81▼ -41.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.12 | $2.32 | $3.88 | $4.25 | $2.97 | $3.07 | $3.28 | $3.94 | $2.36 | $5.40 | $3.01 | $2.75 | $4.75 | $4.50 | $2.75 | $5.25 | |
| P/E | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JYNTJOINT Corp | $8.38 | 59.9x | 7.2x | — | 10.62% | $118.52M |
| RANIRani Therapeutics Holdings, Inc. | $0.84 | — | 2.9x | — | -172.15% | $118.04M |
| QUCYQuantum Cyber N.V. | $1.42 | — | 1.7x | — | -212.53% | $119.38M |
| GNLXGENELUX Corp | $2.66 |
About the company
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- 4
- San Jose, United States
Company description provided by Yahoo Finance.